,

Rev Esp Quimioter 2024; April 17

Artritis séptica por Pasteurella multocida

CARMEN PIÑA DELGADO, MARÍA NIEVES CARMONA TELLO, MARGARITA BOLAÑOS RIVERO, MARÍA DEL CARMEN LAVILLA SALGADO, ISABEL DE MIGUEL MARTÍNEZ

Published: 17 April 2024

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/019.2024

Rev Esp Quimioter 2024; April 17 [Texto completo PDF]


</a

,

Rev Esp Quimioter 2024, April 12

The role of viral diagnostic tests in respiratory tract infections: moving forward

RAÚL ORTÍZ DE LEJARAZU, JOSÉ M. EIROS, FRANCISCO LÓPEZ-MEDRANO, MILAGROS MONTES, ALFREDO TAGARRO, MARÍA TOMÁS

Published: 12 April 2024

http://www.doi.org/10.37201/req/150.2023

The increased knowledge on virology and the increased potential of their diagnostic has risen several relevant question about the role of an early viral diagnosis and potential early treatment on the management of respiratory tract infections (RTI). In order to further understand the role of viral diagnostic tests in the management of RTI, a panel of experts was convened to discuss about their potential role, beyond what had been agreed in Influenza. The objective of this panel was to define the plausible role of aetiologic viral diagnostic into clinical management; make recommendations on the potential expanded use of such tests in the future and define some gaps in the management of RTI. Molecular Infection Viral Diagnostic (mIVD) tests should be used in all adult patients admitted to Hospital with RTI, and in paediatric patients requiring admission or who would be referred to another hospital for more specialised care. The increased use of mIVD will not only reduce the inappropriate use of antibiotics so reducing the antibiotic microbe resistance, but also will improve the outcome of the patient if an aetiologic viral therapy can be warranted, saving resource requirements and improving patient flows. Implementing IVD testing in RTI has various organizational benefits as well, but expanding its use into clinical settings would need a cost-effectiveness strategy and budget impact assessment.

Rev Esp Quimioter 2024; April 12 [Full-text PDF] [Supplementary material PDF]


</a

,

Rev Esp Quimioter 2024, April 11

Biofilm prevention concentration of clarithromycin against clinically relevant species of nontuberculous mycobacteria

ABRAR SENHAJI-KACHA, ARIJ AKIR, ANTONIO BRONCANO-LAVADO, JAIME ESTEBAN

Published: 11 April 2024

http://www.doi.org/10.37201/req/014.2024

Introduction. Mycobacterium avium complex (MAC) and Mycobacterium abscessus are a group of nontuberculous mycobacteria (NTM) that have been described as human pathogens. Their ability to develop biofilms in tissues and medical devices is one of the most important pathogenicity factors, with important implications in diagnosis and treatment. Macrolides are usually considered one of the bases of this treatment.
Methods. Here we have studied the biofilm prevention concentration (BPC) of 16 strains (n=16) with clarithromycin to avoid the biofilm development by these NTM.
Results. In this study, all M. abscessus strains have similar BPC, while MAC strains showed different values. For MAC the concentrations ranged between 1-16 mg/L, while for M. abscessus the concentration was 32 mg/L for all strains except one that was 64 mg/L.
Conclusions. These results open the possibility of using macrolides for the prevention of biofilm development in patients with a risk of developing NTM disease.

Rev Esp Quimioter 2024; April 11 [Full-text PDF]


</a

,

Rev Esp Quimioter 2024; April 10

Endocarditis infecciosa por Listeria monocytogenes: Caso tratado sin intervención quirúrgica con adecuada evolución clínica

TELMO FERNANDEZ DE CASADEVANTE, XABIER CAMINO, AINHOA ARTECHE, ANA ALONSO, PAUL MARTINAGE

Published: 10 April 2024

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/141.2023

Rev Esp Quimioter 2024; April 10 [Texto completo PDF]


</a

,

Rev Esp Quimioter 2024, April 9

Azithromycin and moxifloxacin resistance determinants in Mycoplasma genitalium in Lleida, Spain

LUCÍA FRAILE GARCÍA, JESÚS ARAMBURU ARNUELOS, ÉRIC LÓPEZ GONZÁLEZ, ALBA BELLÉS-BELLÉS, ALBA MUÑOZ SANTA, ELENA SÁNCHEZ BÁSCONES, SARAY MORMENEO BAYO, ALBERT BERNET SÁNCHEZ, IVÁN PRATS SÁNCHEZ, ALEJANDRO CUMPLIDO PORTILLO, MERCÈ GARCÍA GONZÁLEZ

Published: 9 April 2024

http://www.doi.org/10.37201/req/015.2024

Introduction. Mycoplasma genitalium (MG) is a microorganism related to sexually transmitted infections. Antibiotic resistance of MG leads to an increase in treatment failure rates and the persistence of the infection. The aim of this study was to describe the most frequent mutations associated with azithromycin and moxifloxacin resistance in our geographical area.
Material and methods. A prospective study from May 2019 to May 2023 was performed. MG-positive samples were collected. Real-time PCRs (AllplexTM MG & AziR Assay and AllplexTM MG & MoxiR Assay, Seegene) were performed in MG positive samples to detect mutations in 23S rRNA V domain and parC gene.
Results. A 37.1% of samples presented resistance determinants to azithromycin and the most common mutation detected was A2059G (57.9%). Resistance to moxifloxacin was studied in 72 azithromycin-resistant samples and 36.1% showed mutations, being G248T the most prevalent (73.1%).
Conclusions. The resistance to different lines of treat ment suggests the need for a targeted therapy and the performing of a test of cure afterwards.

Rev Esp Quimioter 2024; April 9 [Full-text PDF]


</a

,

Rev Esp Quimioter 2024; March 27

Diagnóstico rápido de un caso de meningitis posquirúrgica con BioFire® Joint Infection Panel

BELÉN CUADRADO GARCÍA, ANA MADUEÑO ALONSO, ANA MARTÍN BERMÚDEZ, LUCÍA ROMERO-ACEVEDO, PAULA PÉREZ ORÁN, MARÍA LECUONA FERNÁNDEZ

Published: 27 March 2024

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/009.2024

Rev Esp Quimioter 2024; March 27 [Texto completo PDF]


</a

,

Rev Esp Quimioter 2024; March 27

Dalbavancin as long-term treatment in Corynebacterium striatum Infections: a literature review

MIGUEL CAMARA-RODRIGUEZ, FRANCISCO JOVER-DIAZ, ELISABET DELGADO-SÁNCHEZ, ANA INFANTE-URRÍOS, JORGE PERIS-GARCÍA

Published: 27 March 2024

LETTER TO THE EDITOR

http://www.doi.org/10.37201/req/149.2023

Rev Esp Quimioter 2024; March 27 [Full-text PDF]


</a

,

Rev Esp Quimioter 2024, March 23

Usefulness of the MPB-INFURG-SEMES model to predict bacteremia in the patient with solid tumor in the Emergency Department

MARÍA MUELAS GONZÁLEZ, ELENA TORNER MARCHESI, GABRIELA PELÁEZ DÍAZ, MARTA RAMOS ARANGUEZ, JAVIER CABAÑAS MORAFRAILE, WILLIAM LÓPEZ FORERO, RAFAEL RUBIO DÍAZ, JUAN GONZÁLEZ DEL CASTILLO, FRANCISCO JAVIER CANDEL, AGUSTÍN JULIÁN-JIMÉNEZ, EN NOMBRE DEL GRUPO INFURG SEMES

Published: 23 March 2024

http://www.doi.org/10.37201/req/004.2024

Objective. To analyse a new risk score to predict bacteremia (MPB-INFURG-SEMES) in the patients with solid tumor attender for infection in the emergency departments (ED).
Patients and methods. Prospective, multicenter observational cohort study of blood cultures (BC) obtained from adult patients with solid neoplasia treated in 63 EDs for infection from November 1, 2019, to March 31, 2020. The predictive ability of the model was analyzed with the area under the Receiver Operating Characteristic curve (AUC-ROC). The prognostic performance for true bacteremia was calculated with the chosen cut-off for getting the sensitivity, specificity, positive predictive value and negative predictive value.
Results. A total of 857 blood samples wered cultured. True cases of bacteremia were confirmed in 196 (22.9%). The remaining 661 cultures (77.1%) wered negative. And, 42 (4.9%) were judged to be contaminated. The model’s area under the receiver operating characteristic curve was 0.923 (95% CI,0.896-0.950). The prognostic performance with a model’s cut-off value of ≥ 5 points achieved 95.74% (95% CI, 94,92-96.56) sensitivity, 76.06% (95% CI, 75.24-76.88) specificity, 53.42%(95% CI, 52.60-54.24) positive predictive value and 98.48% (95% CI, 97.66- 99.30) negative predictive value.
Conclusion. The MPB-INFURG-SEMES score is useful for predicting bacteremia in the adults patients with solid tumor seen in the ED.

Rev Esp Quimioter 2024; March 23 [Texto completo PDF]


</a

,

Rev Esp Quimioter 2024, March 22

Meningococcal meningitis in Spain in the Horizon 2030: A position paper

FERNANDO MORAGA-LLOP, ELENA ANDRADAS, LUIS CARLOS BLESA-BAVIERA, RAFAEL CANTÓN, JUAN GONZÁLEZ DEL CASTILLO, FEDERICO MARTINÓN-TORRES, ELENA MOYA, ANTONI TRILLA, JULIO VAZQUEZ, RODOLFO JAVIER VILLENA, JULIÁN RUIZ-GALIANA, PILAR DE LUCAS RAMOS, ALEJANDRA GARCÍA-BOTELLA, ALBERTO GARCÍA-LLEDÓ, TERESA HERNÁNDEZ-SAMPELAYO, JAVIER GÓMEZ-PAVÓN, MARI CRUZ MARTÍN-DELGADO, FRANCISCO JAVIER MARTÍN SÁNCHEZ, MANUEL MARTÍNEZ-SELLÉS, JOSÉ MARÍA MOLERO GARCÍA, SANTIAGO MORENO GUILLÉN, FERNANDO RODRÍGUEZ-ARTALEJO, EMILIO BOUZA

Published: 22 March 2024

http://www.doi.org/10.37201/req/023.2024

Meningococcal meningitis (MM) and invasive meningococcal disease remain a major public health problem that generates enormous public alarm. It is caused by Neisseria meningitidis, a Gram-negative diplococcus with an enormous capacity for acute and rapidly progressive disease, both episodic and epidemic in nature, with early diagnosis and treatment playing a major role. It occurs at any age, but is most common in children under 5 years of age followed by adolescents. Although most cases occur in healthy people, the incidence is higher in certain risk groups. Despite advances in reducing the incidence, it is estimated that in 2017 there were around 5 million new cases of MM worldwide, causing approximately 290,000 deaths and a cumulative loss of about 20,000,000 years of healthy life. In Spain, in the 2021/22 season, 108 microbiologically confirmed cases of MM were reported, corresponding to an incidence rate of 0.23 cases per 100,000 inhabitants. This is a curable and, above all, vaccine-preventable disease, for which the World Health Organisation has drawn up a roadmap with the aim of reducing mortality and sequelae by 2030. For all these reasons, the Illustrious Official College of Physicians of Madrid (ICOMEM) and the Medical Associations of 8 other provinces of Spain, have prepared this opinion document on the situation of MM in Spain and the resources and preparation for the fight against it in our country. The COVID-19 and Emerging Pathogens Committee of ICOMEM has invited experts in the field to participate in the elaboration of this document.

Rev Esp Quimioter 2024; March 22 [Full-text PDF]


</a

,

Rev Esp Quimioter 2024, March 21

Microbiological and epidemiological features of respiratory syncytial virus

IVÁN SANZ-MUÑOZ, LAURA SÁNCHEZ-DE PRADA, JAVIER CASTRODEZA-SANZ, JOSÉ M EIROS

Published: 21 Mach 2024

http://www.doi.org/10.37201/req/006.2024

The properties of the main surface proteins and the viral cycle of the respiratory syncytial virus (RSV) make it an attractive pathogen from the perspective of microbiology. The virus gets its name from the manner it infects cells, which enables it to produce syncytia, which allow the virus’ genetic material to move across cells without having to release viral offspring to the cellular exterior, reducing immune system identification. This causes a disease with a high impact in both children and adults over 60, which has sparked the development of several preventive interventions based on vaccines and monoclonal antibodies for both age groups. The epidemiological characteristics of this virus, which circulates in epidemics throughout the coldest months of the year and exhibits a marked genetic and antigenic drift due to its high mutation capability, must be taken into consideration while using these preventive methods. The most important microbiological and epidemiological elements of RSV are covered in this study, along with how they have affected the creation of preventive medications and their use in the future.

Rev Esp Quimioter 2024; March 21 [Full-text PDF]


</a